main logo

Blog

Exactus Appoints John Price as Independent Director and Chairman of the Audit Committee

GLEN ALLEN, VA / ACCESSWIRE / February 13, 2019 / Exactus Inc. (OTCQB: EXDI), a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products and point of care diagnostics, is pleased to announce the appointment of John Price to the Board of Directors and Chairman of the Audit Committee. Mr. Price currently serves as Chief Financial Officer of SCWorx Corp., (WORX), provider of data normalization, application interoperability and big data analytics within the healthcare provider market, where he has been since 2016.

Philip Young, CEO of Exactus said, “We welcome John to our board. We look forward to benefiting from his vast financial experience, as we begin to position Exactus for a potential up-list to NASDAQ. Just last week, John spearheaded the successful initial listing for SCWorx on the Nasdaq, as its CFO.”

Previously, Mr. Price was Chief Financial Officer of MusclePharm Corporation, a publicly-traded nutritional supplement company. Prior to joining MusclePharm in 2013, he served as Vice President of Finance – North America, at Opera Software, a Norwegian public company focused on digital advertising. He started his career in finance serving various roles at Ernst & Young LLP. Mr. Price has been a certified public accountant (currently inactive) since 2000. He is a graduate of Pennsylvania State University.

Upon joining Exactus Mr. Price commented, ”I am excited to augment the strong board and experienced management team in place at Exactus and look forward to helping the company reach its full potential in the dynamic hemp derived CBD market.”

For information about our products and availability please call 804-205-5036 or email, [email protected].

About Exactus:

Exactus, Inc., is a healthcare company pursuing opportunities in two distinct business segments, Hemp derived, Cannabidiol, which is more commonly referred to as CBD. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. That amount has not been shown to make a person feel “high.” THC is the psychoactive compound found in cannabis. The company is also developing point of care diagnostics. For more information about Exactus: www.exactusinc.com.

Investor Notice

Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under “Risk Factors” in Item 1A of our most recent Form 10-K for the fiscal year ended December 31, 2017 filed with the Securities and Exchange Commission (the “SEC”) on April 2, 2018 and under the heading ”Risk Factors” in our Current Report on Form 8-K filed with the SEC on January 14, 2019, and in other periodic and current reports we file with the SEC. If any of these risks were to occur, our business, financial condition or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See “Safe Harbor” below.

Safe Harbor – Forward Looking Statements

The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic and current filings with the SEC, including the factors described in the sections entitled “Risk Factors”, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company does not undertake any obligation to update forward-looking statements contained in this press release.

For more information:

Company Contact:

Andrew Johnson
509.999.9696

[email protected]

SOURCE: Exactus Inc.
Other Products
Top Rated Products

Exactus Appoints Seasoned Industry Veteran Jonathan Gilbert As Executive Chairman of the Board

Former Scythian Biosciences Founder and CEO Assumes Newly Created Position

GLEN ALLEN, VA / ACCESSWIRE / February 12, 2019 / Exactus Inc. (OTCQB: EXDI) a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products and point of care diagnostics, is pleased to announce the appointment of Jonathan Gilbert to the newly created position of Executive Chairman. Mr. Gilbert founded one of the first companies to sponsor research into the medical efficacy and benefits of CBD therapies at Scythian Biosciences, Corp. where he held the position of Chief Executive Officer until its transformation to what is now Sol Global Investments (SOL; SOLCF). Mr. Gilbert successfully navigated several successful capital raises from major institutions and strategic corporate investors, including a major infusion of $10 million from Canadian-based Aphria, Inc. (APHA; Mkt.Cap ~$2B). Scythian successfully raised over $40 million during his tenure and thereafter. Scythian’s ongoing research at the University of Miami seeks to determine a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.

Mr. Gilbert will assume the position of Executive Chairman effective immediately and will be responsible for assisting the executive team with his knowledge of capital markets and evaluating opportunities to pursue farm and hemp production worldwide. Mr. Gilbert has been endorsed by Exactus’ development partner and largest shareholder, Ceed2Med, LLC.

Ceed2Med is becoming an established leader in CBD technology, including water soluble and effective bioavailability technology. It is expanding its offerings to include CBG, CBN, organic full spectrum and broad spectrum products, each of which offer full chain of custody accountability from the seed to the shelf from certified cGMP production facilities. Ceed2Med offers Exactus experienced personnel who, since 2014, have been engaged in many aspects of domestic and international hemp production, including farming, processing and production, providing access to expertise in the fields of genetics, product development and distribution. Together with Ceed2Med, Exactus is opening new sales channels and focusing on the creation of additional distribution partnerships.

Philip Young, CEO of Exactus said, “We are excited to welcome Mr. Gilbert to our board and we are honored to have him serve as our Chairman. His experience in the public markets and the CBD sector in particular, will enhance Exactus’ ability to navigate the capital markets effectively and determine our future direction.”

Emiliano Aloi, of Ceed2Med and a member of the Exactus Board of Advisors said: “We look forward to working with Mr. Gilbert. His knowledge of the needs and opportunities available to Exactus will allow us to collectively evaluate new opportunities. We anticipate that our access to various opportunities in Oregon and Kentucky will be helpful as we look forward to expanding Exactus’ financial capacity, allowing it to develop into an independent and cooperative farming partner. With our previous experience in Uruguay, and future opportunities in places like Puerto Rico, Jamaica and elsewhere, we have the runway to add thousands of new acres, domestically and internationally. We look forward to working with Exactus as its preferred premium supplier and development partner.”

For information about our products and availability please call 804-205-5036 or email, [email protected].

About Exactus:

Exactus, Inc., is a healthcare company pursuing opportunities in two distinct business segments, Hemp derived, Cannabidiol, which is more commonly referred to as CBD. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. That amount has not been shown to make a person feel “high.” THC is the psychoactive compound found in cannabis. The company is also developing point of care diagnostics.

Investor Notice

Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under “Risk Factors” in Item 1A of our most recent Form 10-K for the fiscal year ended December 31, 2017 filed with the Securities and Exchange Commission (the “SEC”) on April 2, 2018 and under the heading “Risk Factors” in our Current Report on Form 8-K filed with the SEC on January 14, 2019, and in other periodic and current reports we file with the SEC. If any of these risks were to occur, our business, financial condition or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See “Safe Harbor” below.

Safe Harbor – Forward Looking Statements

The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic and current filings with the SEC, including the factors described in the sections entitled “Risk Factors”, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company does not undertake any obligation to update forward-looking statements contained in this press release.

For more information:

Company Contact:

Andrew Johnson
509.999.9696
[email protected]

SOURCE: Exactus Inc.
Other Products
Top Rated Products

Exactus Releases Annual Shareholder Letter

GLENN ALLEN, VA / ACCESSWIRE / February 7, 2019 / Exactus Inc. (OTCQB: EXDI)

Dear Fellow Shareholders:

Over the last several months the Exactus team and its advisors have been evaluating numerous opportunities and relationships to increase shareholder value.

We are pleased to have identified the rapidly growing hemp-based Cannabidiol (CBD) market as a valuable target for a new company focus. Moving forward we will be developing this opportunity. We will focus on leveraging our recently established relationships to pursue a vertically integrated company that will have control of the entire product life cycle.

This decision was based in part on the passing of The Hemp Farming Act of 2018. The Act was signed into law during December 2018 and removes hemp (cannabis with less than 0.3% THC) from the Schedule I controlled substances list. Following passage, CBD derived from industrial hemp became legal in the US under federal law and in all 50 states, opening the door to develop and sell hemp-based CBD products nationwide

The CBD market is poised for extraordinary growth. The Brightfield Group, an industry leading market research firm, estimates the total CBD market to be ~$22B in 2022. This includes growth in specialty retailers doubling, and the medical practitioner distribution channel growing by 400% by 2022.

Exactus started 2019 with momentum, entering into a Master Product Development and Supply Agreement with Ceed2Med, LLC (www.ceed2med.com). Ceed2Med owns and utilizes cGMP facilities in the United States and has expertise, resources, skills and experience in growing and processing active phyto-cannabinoid (CBD) rich ingredients into isolates, distillates, water soluble, and proprietary formulations, including full-spectrum and broad-spectrum products. It is important to note that all our CBD products will have a verifiable history and chain of custody from the seed through to the final consumer product. To be clear, our Hemp derived CBD products are grown and cultivated to only produce CBD that will not cause the psycho activity found in THC based cannabis products or cannabis derived CBD, and we have chosen to not engage in the cannabis business which continues to face legal challenges at the federal level.

We also plan to evaluate strategic acquisitions and opportunities to acquire existing retail distribution channels to fast track our growth. Hundreds of small CBD distributors have carved out niche markets which we believe are poised for acquisition in a roll-up strategy, and we have begun to evaluate several potential opportunities.

Our partnership with Ceed2Med provides Exactus a turnkey solution to enter into this explosive market. Our goal is to rapidly establish wholesale and retail sales channels for CBD end-products to be sold to humans, such as nutraceuticals and supplements, as well as pet and farm products for animal health. Exactus expects to offer a number of products including tinctures, edibles, capsules and topical solutions which we expect to begin marketing by the end of first quarter 2019 under our own brand and white label options. These products will be manufactured for us by Ceed2Med.

As a part of our new focus, we have appointed three new board members including Kevin Esval, Jeffrey Thompson and Ken Puzder who bring extensive and successful entrepreneurial backgrounds in investment banking, technology and business to support us as we achieve our goals.

Kevin Esval currently serves as Executive Managing Director and CCO of VelocityHealth Securities, a company he founded in 2000. Prior to founding VelocityHealth Securities, Mr. Esval served as a divisional SVP and COO for UnitedHealth Group where he was instrumental in growing his division from $0 to $400 million at his departure.

Jeffrey Thompson is the CEO and Founder of Red Cat Propware Inc., a provider of cloud-based analytics, storage, and services for drone aircraft. Mr. Thompson founded Towerstream Corp. which became publicly traded on the NASDAQ in June 2007 as well as EdgeNet Inc., a privately held Internet service provider which was sold to Citadel Broadcasting Corporation in 1997.

Kenneth Puzder serves as the Chief Financial Officer of Ceed2Med and Co-founder, CFO and Managing Member of the Lutkens Group, LLC. Mr. Puzder specializes in financial leadership, mergers and acquisitions, restructurings and turnarounds. Mr. Puzder previously served in various positions with the Arby’s Restaurant Group (“ARG”) family of companies, including CFO of AFA Service Corporation.

We are also establishing a world-class advisory board led by Emiliano Aloi. Mr. Aloi is a co-founder of Ceed2Med and previously served as Vice President and Director of Strategic Development for GenCanna Global, Inc. Mr. Aloi is an agribusiness expert skilled in supply and market development.

Our plan is to expand our board of advisors with additional experts that will assist us with CBD, FDA regulatory and product development.

In conclusion, 2019 is looking to be a pivotal year as we embark on this amazing opportunity. I look forward to keeping you updated on our progress as we are eager to launch new products, build out distribution channels, and increase investor awareness and shareholder value.

On behalf of the Exactus management, Board of Directors, and employees, I want to personally thank you for your continued support.

Sincerely,

Phil J Young

Chairman & CEO

For information about our products and availability please call 804-205-5036 or email, [email protected].

About Exactus:

Exactus, Inc., is a healthcare company pursuing opportunities in two distinct business segments, Hemp derived, Cannabidiol, which is more commonly referred to as CBD. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. THC is the psychoactive compound found in cannabis. The company is also developing point of care diagnostics.

Forward Looking Statements:

This letter includes forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, but are not limited to, the impact of competitive firms, the ability to meet regulatory requirements, the ability to manage growth, the ability to acquire and retain clientele, acquisitions of technology, equipment, or human resources, the ability to access new capital, the effect of economic business conditions, and the ability to attract and retain skilled personnel. We are not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

For more information:

Company Contacts:

Corporate Communications Contact:
Tim Ryan, EVP & Director
[email protected]
646.342.6199

Philip J. Young, Chairman and CEO
[email protected]

SOURCE: Exactus Inc.
Other Products
Top Rated Products

Exactus Inc. Announces Retirement of Convertible Notes

Simplifies Capital Structure as it Positions for Growth

GLENN ALLEN, VA / ACCESSWIRE / January 30, 2019 / Exactus Inc. (OTCQB: EXDI) a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products and point of care diagnostics, is pleased to announce that it has reached agreement with the holders of its currently convertible notes to retire those notes. The Company agreed to issue a new series of preferred stock designated as Series A Convertible Preferred Stock in place of the notes.

As a result, the Company’s convertible notes which had been currently convertible at variable prices reflecting a predetermined discount to market prices, have been retired and the Company has eliminated this indebtedness. Each share of Series A Convertible Preferred Stock, stated value $1.00 per share, is convertible into the Company’s Common Stock at a fixed conversion price of $0.025 per share which upon full conversion represents approximately 37 million shares of Common Stock.

Philip Young, chairman and CEO, commented ”We are pleased to announce the restructuring we completed with our note holders. The elimination of several variable rate, floating price, convertible notes has strengthened our balance sheet and simplified our capital structure as we position the company for a possible up-listing to a national securities exchange.”

For information about our products and availability please call 804-205-5036 or email, [email protected].

About Exactus:

Exactus, Inc., is a healthcare company pursuing opportunities in two distinct business segments, Hemp derived, Cannabidiol, which is more commonly referred to as CBD. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. THC is the psychoactive compound found in cannabis. The company is also developing point of care diagnostics.

Forward Looking Statements:

This press release includes forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, but are not limited to, the impact of competitive firms, the ability to meet regulatory requirements, the ability to manage growth, the ability to acquire and retain clientele, acquisitions of technology, equipment, or human resources, the ability to access new capital, the effect of economic business conditions, and the ability to attract and retain skilled personnel. We are not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

For more information:

Company Contacts:

Corporate Communications Contact:
Tim Ryan, EVP, Director
[email protected]
646.342.6199

SOURCE: Exactus Inc.

Exactus Appoints New Members to Its Board of Directors

Adds Expertise in Finance Healthcare & Operations

GLEN ALLEN, VA / ACCESSWIRE / January 25, 2019 / Exactus Inc. (OTCQB: EXDI) a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products and point of care diagnostics, is pleased to announce the election of three new board members including Kevin Esval, Jeffrey Thompson and Ken Puzder. With these three additions, the Exactus Board of Directors expands to five.

Philip Young, Chairman & CEO of Exactus said, “We are honored to welcome Messieurs Esval, Thompson and Puzder to our board. Their extensive and varied background will support Exactus from operations to finance as we enter into the rapidly growing CBD market.” Young further commented, “The quality of the board speaks volumes to where the company is headed.”

Kevin Esval currently serves as Executive Managing Director of VelocityHealth Securities. Prior to founding VelocityHealth, Mr. Esval served as a divisional SVP and COO for UnitedHealth Group where he was instrumental in growing his division from startup to $400 million in revenue.

Jeffrey Thompson is the CEO and Founder of Red Cat Propware Inc., a provider of cloud-based analytics, storage, and services for drone aircraft. Mr. Thompson founded Towerstream Corp. which became publicly traded on the NASDAQ in June 2007 as well as EdgeNet Inc., a privately held Internet service provider which was sold to Citadel Broadcasting Corporation in 1997.

Kenneth Puzder serves as the Chief Financial Officer of Ceed2Med, our largest shareholder. Mr. Puzder previously served in various positions with the Arby’s Restaurant Group (“ARG”) family of companies, including CFO of AFA Service Corporation. “In speaking for my fellow board members, I would like to say how excited we are to add our financial, healthcare and executive expertise to help guide management in this exciting opportunity.”

For information about our products and availability please call 804-205-5036 or email, [email protected].

About Exactus:

Exactus, Inc., is a healthcare company pursuing opportunities in two distinct business segments, Hemp derived, Cannabidiol, which is more commonly referred to as CBD. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. That amount has not been shown to make a person feel “high.” THC is the psychoactive compound found in cannabis. The company is also developing point of care diagnostics.

Forward Looking Statements:

This press release includes forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, but are not limited to, the impact of competitive firms, the ability to meet regulatory requirements, the ability to manage growth, the ability to acquire and retain clientele, acquisitions of technology, equipment, or human resources, the ability to access new capital, the effect of economic business conditions, and the ability to attract and retain skilled personnel. We are not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

For more information:

Company Contacts:

Corporate Communications Contact:
Tim Ryan, EVP, Director
[email protected]
646.342.6199

Philip J. Young, Chairman and CEO
[email protected]

SOURCE: Exactus Inc.

Exactus Inc. Announces Entry into Hemp CBD Market

Enters into Supply and Development Agreement with Ceed2Med, LLC

GLEN ALLEN, VA / ACCESSWIRE / January 17, 2019 / Exactus Inc. (OTCQB: EXDI) is pleased to announce its entrance into the CBD market in conjunction with Ceed2Med, LLC’s (“C2M”) acquisition of a controlling ownership interest in Exactus, Inc. and a Master Product Development and Supply Agreement with Ceed2Med, LLC for hemp-based Cannabidiol (“CBD”) products with full genetic traceability. C2M operates and manufactures at cGMP facilities and processes raw material through a number of facilities in order to produce phyto-cannabinoid rich ingredients, including isolates, distillates, water soluble, and proprietary formulations. Exactus has a number of hemp-based CBD products in the pipeline and expects to offer tinctures, edibles, capsules, topical solutions and animal health products manufactured by C2M commencing the first quarter of 2019. C2M has committed 2,500 kilograms annually to Exactus. The founders of C2M established their first CBD business in 2014 and are leaders in CBD innovation.

In December 2018, President Trump signed the $867 billion Farm Bill which recharacterized hemp to the lowest-level listed drug (schedule 5). This clarified that mass hemp production in the United States is federally lawful, as is its transportation across state lines. Hemp is defined in the United States as cannabis with less than 0.3% Tetrahydrocannabinol (“THC”). CBD, a non-psychoactive cannabinoid found in cannabis, has had a surge in popularity over the past several years based on a wide range of potential health benefits and uses.

Philip Young, CEO of Exactus said, “We are thrilled to have such a highly respected partner as we create a new business model in the hemp marketplace. By applying the highest standards, from the initial seed selection all the way through the production and distribution of the commercial product, we plan to be a leader in quality, innovation and commercialization.” Young further commented, “This quality will be evident and part of every product line we produce, whether it is for our proprietary product line or for other commercial partners who want to access our product development pathway.”

Emiliano Ailo, Co-Founder of Ceed2Med added, “Partnering with Exactus is an exciting opportunity for our company. It is an honor to work with a company that has the same commitment to quality and a desire to lead the hemp marketplace with the highest standards. We believe our scientific commitment from seed selection, through cultivation, harvesting and manufacturing, combined with our innovative seed-to-sale traceability is setting the standard in the hemp market and ensures premium pricing and higher product safety over others”

For information about our products and availability please call 804-205-5036 or email, [email protected].

About Exactus:

Exactus, Inc. is a healthcare company pursuing opportunities in two distinct business segments, Hemp derived, THC free CBD and point of care diagnostics.

Forward Looking Statements:

This press release includes forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, but are not limited to, the impact of competitive firms, the ability to meet regulatory requirements, the ability to manage growth, the ability to acquire and retain clientele, acquisitions of technology, equipment, or human resources, the ability to access new capital, the effect of economic business conditions, and the ability to attract and retain skilled personnel. We are not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

For more information:

Company Contacts:

Corporate Communications Contact:
Tim Ryan, EVP, Director
[email protected]
646.342.6199

Philip J. Young, Chairman and CEO
[email protected]

SOURCE: Exactus Inc.

Exactus, Inc. Selected to Participate at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices, foundations and impact investors within health and the life sciences

RICHMOND, VA / ACCESSWIRE / May 9, 2017 / Exactus, Inc. (OTCQB: EXDI), a life science company that is developing and commercializing ultra-fast, handheld, point-of-care (“POC”) diagnostic tools powering informed patient management, announced it has been selected to present at the Cavendish Global Health Impact Forum taking place today in Washington, D.C., co-hosted with the Virginia Biotechnology Association (“VirginiaBio”). The Forum provides an environment for family offices, foundations and impact investors to develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, impact investors, research institutions, private-sector companies and nonprofit organizations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of impact investors, Cavendish Impact Forums are hosted by leading institutions around the world and take place four times each year.

Michael Moffat, Cavendish co-founder and Chairman explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Exactus’ research and scientific insights in measuring proteolytic enzymes in the blood and diagnose cancer positions them to make a major contribution to diagnostics and improving patient outcomes.”

“We are honored to be selected to present at this unique event. It is further recognition of our innovative approach to assessing the fibrinolytic status of patients in a broad range of applications with the use of our FibriLyzer™ which could provide the basis for improved management of patients who are at-risk of hemorrhage,” said Exactus CEO Philip Young. “We welcome the chance to interact with many of world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

Cavendish Global consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides impact investors with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.

About Exactus Inc.

Exactus is a publicly traded life science company based in Richmond, Virginia that is developing and commercializing point-of-care (POC) diagnostics for measuring proteolytic enzymes in the blood. We anticipate our lead product, the FibriLyzer™, will provide a simple and affordable means to assess the fibrinolytic status of patients in a broad range of applications and that the use of the FibriLyzer™ could provide the basis for improved management of patients who are at-risk of hemorrhage, speeding treatment decisions and potentially improving patient outcomes and saving money.

Our second product candidate, the MatriLyzer™, may be used to detect the recurrence of cancer, and can be used as an at-home monitoring device or during routine office visits. The appearance of elevated levels of collagenase, the enzyme that degrades collagen, have been proven to be an early hallmark of cancer. The MatriLyzer™ can communicate directly with the attending oncologist via a smart phone application to ensure that (i) the tests are being used properly and (ii) when collagenase levels are elevated signaling the need for the patient to have a more thorough examination. For more information about Exactus, please visit our website at: www.exactusinc.com.

For more information: www.exactusinc.com

About Cavendish Global (http://cavendishglobal.com)

Cavendish Global is a peer-to-peer community of paradigm-changing innovators in health and the life sciences; over 200 leading family offices, philanthropists, foundations and impact investors; key opinion leaders and renown institutional partners that share a passion for well-conceived impact investing, sustainable philanthropy and delivering transformative impact. Cavendish provides the resources for innovators to advance their impactful work from mind to marketplace – through connectivity, advisory services, access to key opinion leaders and capital opportunities. Together, the Cavendish community bridges the gaps and accelerates innovation. Cavendish will host Forums in 2017 in Washington, DC, Chicago and Boston. For more information: http://cavendishglobal.com.

Philip J. Young, President and CEO
[email protected]

Corporate Communications Contact:
Tim Ryan, EVP
[email protected]
212.242.7777

Investor Relations Contact:
Robert Haag
Managing Director
IRTH Communications
[email protected]
866.976-4784

SOURCE: Exactus, Inc.

Exactus, Inc. to Present at MedTech Strategist Innovation Summit

RICHMOND, VA / ACCESSWIRE / April 20, 2017 / Exactus, Inc. (OTCQB: EXDI), a life science company that is developing and commercializing ultra-fast, handheld, point-of-care (POC) diagnostic tools powering informed patient management, announced today that the Company management will present at the MedTech Strategist Innovation Summit scheduled for April 25-27, 2017, at The Shelbourne Hotel in Dublin, Ireland. To learn more about the MedTech Strategist Innovation Summit, please click here.

Event: MedTech Strategist Innovation Summit
Location: The Shelbourne Hotel in Dublin, Ireland
Date: April 26, 2017
Time: 9:05 AM DST (4:05 AM EDT)

Exactus CEO Philip Young will deliver a formal presentation and discuss recent business highlights and updates. Management will also be available for one-on-one meetings. To arrange a meeting with management, please contact Tim Ryan at [email protected] or Robert Haag at [email protected].

About The MedTech Strategist

The MedTech Strategist is an information and investment conferences provider focused exclusively on the underserved medtech market. It is led by managing partners and co-editors-in-chief David Cassak and Stephen Levin, along with a seasoned editorial team. The company launched The MedTech Strategist, a publication broadly covering the most important topics and trends in medical devices today, in September 2014. Featuring a wide range of editorial offerings – from interviews with industry leaders to stories on leading companies, profiles of groundbreaking start-ups, and analyses of dynamic clinical markets and technology trends – The MedTech Strategist explores how innovation plays out in all of its various forms – clinical, technological, business model, marketplace, and financing – in the global medical device arena.

About Exactus Inc.

Exactus is a publicly traded life science company based in Richmond, Virginia that is developing and commercializing point-of-care (POC) diagnostics for measuring proteolytic enzymes in the blood. We anticipate our lead product, the FibriLyzer™, will provide a simple and affordable means to assess the fibrinolytic status of patients in a broad range of applications and that the use of the FibriLyzer™ could provide the basis for improved management of patients who are at-risk of hemorrhage, speeding treatment decisions and potentially improving patient outcomes and saving money.

Our second product candidate, the MatriLyzer™, may be used to detect the recurrence of cancer, and can be used as an at-home monitoring device or during routine office visits. The appearance of elevated levels of collagenase, the enzyme that degrades collagen, have been proven to be an early hallmark of cancer. The MatriLyzer™ can communicate directly with the attending oncologist via a smart phone application to ensure that (i) the tests are being used properly and (ii) when collagenase levels are elevated signaling the need for the patient to have a more thorough examination. For more information about Exactus, please visit our website at: www.exactusinc.com.

Forward-Looking Statements

This press release and any statements of representatives and partners of Exactus, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the actual timing for, or actual results of, the Company’s clinical trial described herein or the FDA’s review of such results) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve numerous risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For more information:

Company Contacts:

Philip J. Young, President and CEO
[email protected]

Corporate Communications Contact:

Tim Ryan, EVP
[email protected]
212.242.7777

Investor Relations Contact:

Robert Haag
Managing Director
IRTH Communications
[email protected]
Tel: 866.976.4784

SOURCE: Exactus Inc.

Exactus, Inc. to Present at BIO CEO & Investor Conference

RICHMOND, VA / ACCESSWIRE / February 8, 2017 / Exactus, Inc. (OTCQB: EXDI), a life science company that is developing and planning to commercialize ultra-fast, handheld, point-of-care (POC) diagnostic tools powering informed patient management, announced today that Company management will present at the BIO CEO & Investor Conference on Tuesday, February 14, 2017 at 8:30 AM Eastern Standard Time. The conference will take place February 13-14, 2017 at the Waldorf Astoria, New York, New York.

Exactus CEO, Philip Young will deliver the Company’s corporate presentation and discuss recent business highlights. Management will also be available for one-on-one meetings. To arrange a meeting with management, please contact Tim Ryan at [email protected] or Robert Haag at [email protected].

About the BIO CEO & Investor Conference

Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because its mission is to support industry-wide success, the BIO CEO & Investor Conference presents a broad and unbiased view of investment opportunities.

Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.

BIO CEO & Investor Conference therapeutic workshops feature MDs, CSOs and industry analysts discussing the latest information on pipeline innovation for breakthrough therapeutic topics in biopharma. Seasoned industry executives and analysts delve into timely and relevant business models, deal-making and investment trends on our business roundtables.

About Exactus Inc.

Exactus is a publicly traded life science company based in Richmond, Virginia that is developing and planning to commercialize point-of-care (POC) diagnostics for measuring proteolytic enzymes in the blood. We anticipate our lead product, the FibriLyzer™, will provide a simple and cost effective means to assess the fibrinolytic status of patients in a broad range of applications and that the use of the FibriLyzer™ could provide the basis for improved management of patients who are at-risk of hemorrhage, speeding treatment decisions and potentially improving patient outcomes and possibly improving health economics.

Our second product candidate, the MatriLyzer™, may be used to detect the recurrence of cancer, and can be used as an at-home monitoring device or during routine office visits. The appearance of elevated levels of collagenase, the enzyme that degrades collagen, have been identified as an early hallmark of cancer recurrence and metastasis. The MatriLyzer™ can communicate directly with the attending oncologist via a smart phone application to ensure that (i) the tests are being used properly and (ii) when collagenase levels are elevated signaling the need for the patient to have a more thorough examination. For more information about Exactus, please visit our website at: www.exactusinc.com.

Forward-Looking Statements

This press release and any statements of representatives and partners of Exactus, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the actual timing for, or actual results of, the Company’s clinical trial described herein or the FDA’s review of such results) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve numerous risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For more information:

Company Contacts:

Philip J. Young, President and CEO
[email protected]

Tim Ryan, EVP
[email protected]
212.242.7777

Investor Relations Contact:

Robert Haag
Managing Director
IRTH Communications
[email protected]
Tel: (866) 976-4784

SOURCE: Exactus, Inc.

Exactus, Inc. Announces the Appointment of Dr. James Erickson as Chief Business Officer

RICHMOND, VA / ACCESSWIRE / December 7, 2016 / Exactus, Inc. (OTCQB: EXDI), a life science company that is developing and commercializing ultra-fast, handheld, point-of-care (POC) diagnostic tools powering informed patient management, announced today the appointment of James R. Erickson, Ph.D. as Chief Business Officer. Dr. Erickson will report to Philip J. Young, President and CEO of Exactus.

James started his career as a post-doc at Onyx Pharmaceuticals and has since worked primarily in business development roles for diagnostic and biopharmaceutical companies, including AGY Therapeutics, Entelos and Titan Pharmaceuticals. In 2005 Dr. Erickson founded BayPoint Biosystems, a proteomic company focused on commercializing diagnostics/research tools-oriented technology from the M.D. Anderson Cancer Center. From 2005-2013, BayPoint established biomarker discovery and companion diagnostic development alliances with 12 pharmaceutical, biotechnology, and life science companies. Immediately prior to joining Exactus, James worked as Senior Transaction Advisor at Ferghana Partners, a healthcare investment bank focusing on financings, M&A, and corporate partnering in the diagnostic and therapeutic sectors.

“We are fortunate to have an executive with such a broad background in developing novel diagnostic platforms,” said Mr. Young. “James’ experience in both the technical as well as the transactional aspects of bringing diagnostic to fruition will be an important addition to our management team. We are excited to have James on board as the Company advances towards commercialization of the FibriLyzer™ platform.”

About Exactus, Inc.

Exactus is a publicly traded life science company based in Richmond, Virginia that is developing and commercializing point-of-care (POC) diagnostics for measuring proteolytic enzymes in the blood. We anticipate our lead product, the FibriLyzer™, will provide a simple and affordable means to assess the fibrinolytic status of patients in a broad range of applications and that the use of the FibriLyzer™ could provide the basis for improved management of patients who are at-risk of hemorrhage, speeding treatment decisions and potentially improving patient outcomes and saving money.

Our second product candidate, the MatriLyzer™, may be used to detect the recurrence of cancer, and can be used as an at-home monitoring device or during routine office visits. The appearance of elevated levels of collagenase, the enzyme that degrades collagen, have been proven to be an early hallmark of cancer. The MatriLyzer™ can communicate directly with the attending oncologist via a smart phone application to ensure that (i) the tests are being used properly and (ii) when collagenase levels are elevated signaling the need for the patient to have a more thorough examination. For more information about Exactus, please visit our website at: www.exactusdx.com.

Forward-looking statements

This press release and any statements of representatives and partners of Exactus, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the actual timing for, or actual results of, the Company’s clinical trial described herein or the FDA’s review of such results) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve numerous risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For more information:

Company Contacts:
Philip J. Young, President and CEO
[email protected]

Corporate Communications Contact:
Tim Ryan, EVP
[email protected]
212.242.7777

Investor Relations Contact:
Robert Haag
Irth Communications
[email protected]

SOURCE: Exactus, Inc.